Comparison of Complement Factors and Genetic Polymorphisms of AMD Between Patients With Systemic Lupus Erythematosus (SLE) With and Without Retinal Pseudo-drusen-like Deposits: Case-control Study (PL-AMD)

Comparison of Complement Factors and Genetic Polymorphisms of AMD Between Patients With Systemic Lupus Erythematosus (SLE) With and Without Retinal Pseudo-drusen-like Deposits: Case-control Study (PLAMD)

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT03504540

Acronym

PL-AMD

Enrollment

Registered

2018-04-20

Start date

2018-04-05

Completion date

2021-05-15

Last updated

2021-05-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Age Related Macular Degeneration, Lupus Erythematosus, Lupus Erythematosus, Systemic

Keywords

Lupus Erythematosus, Systemic, Age Related Macular Degeneration, Pseudo-drusen-like deposits

Brief summary

The rationale of this research is to determine if patients with lupus and presenting retinal pseudo-drusen-like deposits have genetic and complement-related similarities with AMD patients. Based on the results obtained, this study could lead to future research that could better target the treatment of patients with lupus or patients with AMD (Age related Macular Degeneration). The primary objective is to check if patients with lupus, treated or not with antimalarial drugs, with pseudo-drusen-like deposits have a different complement profile (functional exploration of complement, complement factors, genetic complement polymorphisms involved in AMD) compared to patients without pseudo-drusen-like deposits.

Interventions

PROCEDUREBlood test

Blood test for complement factors and genetic polymorphisms of AMD analysis

Study design

Observational model

CASE_CONTROL

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to 50 Years

Healthy volunteers

Inclusion criteria

* Systemic lupus erythematosus * Case patients : with pseudo-drusen-like deposit * Control patients : without pseudo-drusen-like deposit

Exclusion criteria

* Patient under a measure of legal protection

Design outcomes

Primary

Measure	Time frame
Comparison of AMD genetic polymorphisms between case and control patients	Baseline
Comparison of complement factors between case and control patients	Baseline

Countries

France

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026